Cover
Cover | Apr. 29, 2024 |
Entity Addresses [Line Items] | |
Document Type | POS AM |
Amendment Flag | true |
Amendment Description | This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) to the Registration Statement on Form F-1 (File No. 333-272693) (the “Registration Statement”) is being filed pursuant to our undertaking in the Registration Statement to update and supplement information contained in the Registration Statement, as originally filed on June 13, 2023, and declared effective by the Securities and Exchange Commission (the “SEC”) on June 28, 2023. The Registration Statement originally covered a resale (the “Offering”) by the selling shareholders identified in this prospectus, of up to an aggregate of 281,126,205 ordinary shares, nominal value £0.001 per share (the “Ordinary Shares”), of Biodexa Pharmaceuticals PLC, represented by 56,225,241 American Depositary Shares (the “Depositary Shares”) consisting of (1) 166,019,415 Ordinary Shares represented by 33,203,883 Depositary Shares, issuable upon the exercise of series C warrants, or Series C Warrants, (2) 110,679,610 Ordinary Shares represented by 22,135,922 Depositary Shares issuable upon the exercise of series D warrants, or Series D Warrants and, together with the Series C Warrants, the Warrants, and (3) 4,427,180 Ordinary Shares represented by 885,436 Depositary Shares issuable upon the exercise of placement agent warrants issued in the Offering. On July 5, 2023, and in an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued. The change in the number of Depositary Shares resulting from the change in ratio has been applied retroactively to all share and per share amounts presented in this prospectus, to the extent applicable. The information included in this filing updates the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 1. Accordingly, this Post-Effective Amendment No. 1 concerns only the offer and sale of ordinary shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised. All applicable registration fees were paid at the time of the original filing of the Registration Statement. |
Entity Registrant Name | Biodexa Pharmaceuticals PLC |
Entity Central Index Key | 0001643918 |
Entity Incorporation, State or Country Code | X0 |
Entity Address, Address Line One | 1 Caspian Point |
Entity Address, Address Line Two | Caspian Way |
Entity Address, City or Town | Cardiff |
Entity Address, Postal Zip Code | CF10 4DQ |
Country Region | +44 |
City Area Code | 29 |
Local Phone Number | 20480 180 |
Entity Filer Category | Non-accelerated Filer |
Entity Emerging Growth Company | false |
Document Creation Date | Apr. 29, 2024 |
Business Contact [Member] | |
Entity Addresses [Line Items] | |
Entity Address, Address Line One | 850 Library Ave. |
Entity Address, Address Line Two | Suite 204 |
Entity Address, City or Town | Newark |
Entity Address, State or Province | DE |
Entity Address, Postal Zip Code | 19711 |
City Area Code | (302) |
Local Phone Number | 738-6680 |
Contact Personnel Name | Donald J. Puglisi |